MTOR and neoplasm: However, recent reports from the phase II BISCAY trial (NCT02546661) have revealed no clinical benefits from the combination of durvalumab (anti‐PD‐L1) and vistusertib (mTOR1/2 inhibitor) for advanced UC [64], despite patient selection based on specific tumor genomic alterations expected to respond mTOR inhibitors.